Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470356 | 1.00 | KDR (0.41) | KDRPIK3CACHEK1CDK7AAK1 | |
| SCHEMBL8739170 | 0.88 | PIK3CA (0.41) | KDRPIK3CACHEK1DYRK1ACYP2D6 | |
| SCHEMBL8739703 | 0.85 | CHEK1 (0.47) | KDRPIK3CACHEK1CDK7CYP2D6 | |
| SCHEMBL15673300 | 0.84 | SRC (0.45) | KDRCHEK1CYP2D6CYP2C19 | |
| SCHEMBL29470282 | 0.84 | SRC (0.45) | KDRCHEK1CYP2D6CYP2C19 | |
| SCHEMBL8739153 | 0.83 | ITK (0.43) | KDRPIK3CACHEK1CDK7CYP2D6 | |
| SCHEMBL29470343 | 0.82 | LRRK2 (0.45) | KDRPIK3CACHEK1CYP2D6CYP2C19 | |
| SCHEMBL15673458 | 0.82 | LRRK2 (0.45) | KDRPIK3CACHEK1CYP2D6CYP2C19 | |
| SCHEMBL6119355 | 0.81 | KDR (0.48) | KDRCHEK1GSK3BDYRK1ACYP2D6 | |
| SCHEMBL29470479 | 0.81 | KDR (0.48) | KDRCHEK1GSK3BDYRK1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-10-18 | — | — | US | claimed |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | claimed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | claimed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-07-09 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012068546-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-11186593-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885PIK3CA 2230/4885CHEK1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.